Download
41416_2024_Article_2746.pdf 840,44KB
WeightNameValue
1000 Titel
  • KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
1000 Autor/in
  1. Budczies, Jan |
  2. Romanovsky, Eva |
  3. Kirchner, Martina |
  4. Neumann, Olaf |
  5. Blasi, Miriam |
  6. Schnorbach, Johannes |
  7. Shah, Rajiv |
  8. Bozorgmehr, Farastuk |
  9. Savai, Rajkumar |
  10. Stiewe, Thorsten |
  11. Peters, Solange |
  12. Schirmacher, Peter |
  13. Thomas, Michael |
  14. Kazdal, Daniel |
  15. Christopoulos, Petros |
  16. Stenzinger, Albrecht |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-06-12
1000 Erschienen in
1000 Quellenangabe
  • 131(3):524-533
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41416-024-02746-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300455/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Predictive biomarkers in use for immunotherapy in advanced non-small cell lung cancer are of limited sensitivity and specificity. We analysed the potential of activating KRAS and pathogenic TP53 mutations to provide additional predictive information.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>The study cohort included 713 consecutive immunotherapy patients with advanced lung adenocarcinomas, negative for actionable genetic alterations. Additionally, two previously published immunotherapy and two surgical patient cohorts were analyzed. Therapy benefit was stratified by KRAS and TP53 mutations. Molecular characteristics underlying KRASmut/TP53mut tumours were revealed by the analysis of TCGA data.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>An interaction between KRAS and TP53 mutations was observed in univariate and multivariate analyses of overall survival (Hazard ratio [HR] = 0.56, <jats:italic>p</jats:italic> = 0.0044 and HR = 0.53, <jats:italic>p</jats:italic> = 0.0021) resulting in a stronger benefit for KRASmut/TP53mut tumours (HR = 0.71, CI 0.55–0.92). This observation was confirmed in immunotherapy cohorts but not observed in surgical cohorts. Tumour mutational burden, proliferation, and PD-L1 mRNA were significantly higher in TP53-mutated tumours, regardless of KRAS status. Genome-wide expression analysis revealed 64 genes, including CX3CL1 (fractalkine), as specific transcriptomic characteristic of KRASmut/TP53mut tumours.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>KRAS/TP53 co-mutation predicts ICI benefit in univariate and multivariate survival analyses and is associated with unique molecular tumour features. Mutation testing of the two genes can be easily implemented using small NGS panels.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Lung Neoplasms/genetics [MeSH]
lokal /692/53/2423
lokal Cohort Studies [MeSH]
lokal Proto-Oncogene Proteins p21(ras)/genetics [MeSH]
lokal Immunotherapy/methods [MeSH]
lokal Male [MeSH]
lokal Adenocarcinoma of Lung/genetics [MeSH]
lokal /631/67/1612/1350
lokal Lung Neoplasms/immunology [MeSH]
lokal /631/114/2415
lokal Female [MeSH]
lokal Adenocarcinoma of Lung/drug therapy [MeSH]
lokal Mutation [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal Adenocarcinoma of Lung/immunology [MeSH]
lokal Tumor Suppressor Protein p53/genetics [MeSH]
lokal Immune Checkpoint Inhibitors/therapeutic use [MeSH]
lokal Article
lokal /631/208/69
lokal Biomarkers, Tumor/genetics [MeSH]
lokal Prognosis [MeSH]
lokal Lung Neoplasms/pathology [MeSH]
lokal Lung Neoplasms/drug therapy [MeSH]
lokal Adenocarcinoma of Lung/pathology [MeSH]
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-6668-5327|https://orcid.org/0000-0002-0059-1977|https://frl.publisso.de/adhoc/uri/S2lyY2huZXIsIE1hcnRpbmE=|https://orcid.org/0000-0003-2684-9187|https://frl.publisso.de/adhoc/uri/Qmxhc2ksIE1pcmlhbQ==|https://frl.publisso.de/adhoc/uri/U2Nobm9yYmFjaCwgSm9oYW5uZXM=|https://frl.publisso.de/adhoc/uri/U2hhaCwgUmFqaXY=|https://frl.publisso.de/adhoc/uri/Qm96b3JnbWVociwgRmFyYXN0dWs=|https://frl.publisso.de/adhoc/uri/U2F2YWksIFJhamt1bWFy|https://orcid.org/0000-0003-0134-7826|https://frl.publisso.de/adhoc/uri/UGV0ZXJzLCBTb2xhbmdl|https://frl.publisso.de/adhoc/uri/U2NoaXJtYWNoZXIsIFBldGVy|https://frl.publisso.de/adhoc/uri/VGhvbWFzLCBNaWNoYWVs|https://orcid.org/0000-0001-8187-3281|https://orcid.org/0000-0002-7966-8980|https://frl.publisso.de/adhoc/uri/U3RlbnppbmdlciwgQWxicmVjaHQ=
1000 Hinweis
  • DeepGreen-ID: 4df18b9816084734ba5ea08e35ec8b11 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Deutsches Zentrum für Lungenforschung |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsches Zentrum für Lungenforschung |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6518703.rdf
1000 Erstellt am 2025-07-05T13:04:34.204+0200
1000 Erstellt von 322
1000 beschreibt frl:6518703
1000 Zuletzt bearbeitet 2025-08-15T20:48:35.522+0200
1000 Objekt bearb. Fri Aug 15 20:48:35 CEST 2025
1000 Vgl. frl:6518703
1000 Oai Id
  1. oai:frl.publisso.de:frl:6518703 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source